Acorda Therapeutics Investor Relations Material
Latest events
Q3 2023
Acorda Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Acorda Therapeutics Inc
Access all reports
Acorda Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for neurological disorders in the United States. The company's lead product is Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS). It also develops ARCUS product for the treatment of acute migraines; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. Acorda Therapeutics' other collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics was incorporated in 1995 and is headquartered in Ardsley, New York.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ACOR
Country
🇺🇸 United States